Interestingly, EGFR-mutant NSCLC patients with a concurrent germline BRCA mutation showed a comparable PFS, and longer OS, in the context of EGFR-TKI treatment compared to patients with the wild-type germline BRCA (36). Here, EGFR is linked to non-small cell lung carcinoma.